STOCK TITAN

ResMed CEO Michael Farrell sells 4,993 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ResMed Inc. Chairman and CEO Michael J. Farrell exercised options for 683 and 4,310 shares at an exercise price of $146.34 per share on November 9, 2026, acquiring the corresponding common shares. He then sold 4,993 shares at a weighted average price of $235.3473 per share. The transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024; the sale involved multiple trades priced from $231.7956 to $237.600. The Lisette and Michael Farrell Family Trust held 2,090 shares indirectly.

Insider Farrell Michael J.
Role Chairman and CEO
Sold 4,993 shs ($1.18M)
Approx. gross sale proceeds $1.18M
Approx. exercise cost $731K
Approx. pre-tax spread $444K
Type Security Shares Price Value
Exercise ResMed Common Stock Options F1, F3 683 $0.00 $0.00
Exercise ResMed Common Stock Options F1, F4 4,310 $0.00 $0.00
Exercise ResMed Common Stock F1 683 $146.34 $100K
Exercise ResMed Common Stock F1 4,310 $146.34 $631K
Sale ResMed Common Stock F1, F2 4,993 $235.3473 $1.18M
Holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock Options — 0 options (Direct); ResMed Common Stock — 479,803 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (4)
  1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
  2. F2. This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price.
  3. F3. Represents date options first become exercisable. Options vest 1/3 per year
  4. F4. Represents date options first become exercisable. Options vest 1/3 per year
Options exercised 683 shares November 9, 2026
Options exercised 4,310 shares November 9, 2026
Exercise price $146.34 per share Options exercised November 9, 2026
Shares sold 4,993 shares November 9, 2026
Weighted average sale price $235.3473 per share Sale on November 9, 2026
Sale prices $231.7956 to $237.600 Multiple trades on November 9, 2026
Indirect trust holding 2,090 shares Lisette and Michael Farrell Family Trust
Rule 10b5-1 plan regulatory
"conducted under a Rule 10b5-1 plan adopted October 31, 2024"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"the price reported above reflects the weighted average sale price"
vest 1/3 per year financial
"Options vest 1/3 per year"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RMD shares did Michael J. Farrell sell, and at what price?

Michael J. Farrell sold 4,993 shares on November 9, 2026, at a weighted average price of $235.3473 per share. The sale was executed in multiple trades priced from $231.7956 to $237.600 under a Rule 10b5-1 plan adopted October 31, 2024.

How many ResMed options did Michael J. Farrell exercise?

On November 9, 2026, Farrell exercised options for 683 and 4,310 shares at an exercise price of $146.34 per share; the corresponding common shares were acquired.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.

(Last)(First)(Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD

(Street)
SAN DIEGO CALIFORNIA 92123

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
ResMed Common Stock11/09/2026M(1)683A$146.34480,486D
ResMed Common Stock11/09/2026M(1)4,310A$146.34484,796D
ResMed Common Stock11/09/2026S(1)4,993D$235.3473(2)479,803D
ResMed Common Stock2,090ILisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
ResMed Common Stock Options$146.3411/09/2026M(1)68311/11/2020(3)11/21/2026ResMed Common Stock683$04,310D
ResMed Common Stock Options$146.3411/09/2026M(1)4,31011/11/2020(4)11/21/2026ResMed Common Stock4,310$00D
Explanation of Responses:
1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. This transaction was executed in multiple trades at prices ranging from $231.7956 - $237.600. The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year
4. Represents date options first become exercisable. Options vest 1/3 per year
/s/ Michael J. Farrell, Chairman and CEO11/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading